Paul Field is assisting PharmAust with its partnering campaign for monepantel. He brings over 30 years of business development experience across a range of therapeutic areas, including neurodegenerative diseases, and he maintains a deep network in the global biopharmaceutical industry. His experience includes business development roles at Cerecin, Marinova, BioCurate and other companies, and he serves on the Boards of NASDAQ-listed 60 Degrees Pharmaceuticals and Wintermute Biomedical. He is a Fellow of the Australian Institute of Company Directors (FAICD). Paul is a member of the investment committee at the Horizon 3 Healthcare Fund in Melbourne. Previously, he was the life sciences specialist at Austrade, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research in CNS disorders, infectious diseases, cancer, and other therapeutic areas.
